The combination of the anti-viral agents, zidovudine (AZT) and interferon-␣ (IFN), is a potent treatment of HTLV-I-associated adult T cell leukemia/lymphoma (ATL). In this study we investigate the possible mechanism of action of this combination by examining several cellular parameters including cell proliferation, cell cycle distribution and apoptosis. The ATL-derived T cell lines HuT-102 and MT-2 served as models. HTLV-I negative T cell lines (CEM and Jurkat) were used as controls. No significant modification of cell growth was observed except at suprapharmacological doses of AZT and IFN. Moreover, these effects were less pronounced in HTLV-I-infected cell lines compared to control cell lines. AZT and IFN treatment did not induce any significant modification of the expression of bcl-2 and p53. Interestingly no in vitro cytotoxic effect of AZT/IFN combination was observed on fresh leukemic cells derived from an acute ATL patient at diagnosis despite achievement of in vivo complete remission using the same therapy. These results suggest that the therapeutic effect of AZT and IFN is not through a direct cytotoxic effect of these drugs on the leukemic cells. Leukemia (2000) 14, 716-721.
Introduction
Adult T cell leukemia/lymphoma (ATL) is an aggressive lympho-proliferative disorder associated with the human T cell lymphotropic virus type I (HTLV-I).
1 ATL-associated tumor cells are constitutively activated CD4 + T cells with characteristic convoluted nuclei and basophilic cytoplasm. 2 ATL carries a bad prognosis due to an intrinsic resistance of leukemic cells to conventional or even high doses of chemotherapy and the associated severe immunosuppression. Combination chemotherapy regimens, in particular those designed for treatment of aggressive non-Hodgkin lymphoma or acute lymphoblastic leukemia, are not effective in the treatment of ATL patients, with a median survival of about 6 months in the acute form. 3 Recent important advances in the treatment of ATL were reported in two independent phase II studies [4] [5] [6] using the combination of an anti-retroviral agent zidovudine (AZT) and interferon-␣ (IFN). This combination produces a high response rate in ATL patients, especially in the acute ATL type and prolongs survival.
This new approach in treating ATL patients raises the important question of the mechanism of action of the combination of AZT and IFN. Chemotherapeutic agents exert their effects on cells through alteration of cell growth. These effects are mainly due to cell cycle arrest and/or induction of apoptosis. 7 In this manuscript, we investigated the potential cytotoxic effect of the combination of AZT and IFN by exam- ining several cellular parameters including cell proliferation, cell cycle distribution and apoptosis. We also examined the expression of the T cell activation markers that are characteristic of ATL cells, as well as the level of expression of some apoptosis or cell cycle regulators (bcl-2 and p53). In this study we report evidence against a direct cytotoxic effect of this combination in HTLV-I-infected cell lines. Similar results were obtained using fresh ATL cells from an acute ATL patient who achieved complete remission (CR) under AZT/IFN therapy.
Materials and methods

Case report
A 71-year-old woman was hospitalized because of fatigue and weight loss. Physical examination showed splenomegaly, enlarged cervical and axillary lymph nodes, skin infiltration of hands and generalized erythroderma. CBC showed hyperleukocytosis with 61 000 WBC/mm 3 and 77% lymphocytes. The lymphocytes exhibited ATL features with the typical flower cell morphology, and CD4
+
, CD25
+ and HLA DR + phenotype. LDH level was elevated (× 3 N) and calcemia was elevated to 3.16 mmol/l. Skin biopsy was consistent with epidermotropic lymphoma. CT of chest, abdomen and pelvis and CSF examination were normal. The patient was seropositive for HTLV-I, and monoclonal integration of the HTLV-I proviral DNA in tumor cells was documented by Southern blot analysis. The diagnosis was that of acute ATL. Treatment with zidovudine (Retrovir 1 g/day p.o.) and IFN (Roferon 9 M IU/day subcutaneously) was started. She responded slowly to this treatment and entered into CR after 8 months. Hematological toxicity led to dose reduction of IFN (4.5 M IU/day) and zidovudine (600 mg/day). Four years later, she is still in CR on maintenance therapy.
Reagents and drugs
AZT (Glaxo-Wellcome, London, UK) and recombinant IFN (Hoffman-La Roche, Basel, Switzerland) were prepared as stock solutions in normal saline. Working stocks were diluted in RPMI 1640 culture medium (Gibco-BRL, Gaithersburg, MD, USA) supplemented with 10% heat-inactivated fetal calf serum (Gibco-BRL). The in vitro dose of 100 U/ml of IFN and 5 M of AZT corresponds to the pharmacological level in vivo. Two other drug concentrations of IFN (10 U/ml and 1000 U/ml) and of AZT (0.5 M and 50 M) were used to span three log magnitudes.
Cell lines
HuT-102 and MT-2 cell lines served as examples of HTLV-Iinfected T cells. These cell lines, derived from ATL patients, are of the T helper phenotype (CD4 + ), constitutively express the interleukin-2 (IL-2) receptor alpha chain (CD25), and are independent of IL-2 for continued growth. In addition, they produce HTLV-I viral particles with a constitutive expression of the HTLV-I proteins. 8, 9 As control, the HTLV-I negative CD4 + T cell lines, CEM and Jurkat were used. Cell lines were seeded at 1 × 10 5 cells/ml in RPMI-1640 medium containing 10% heat inactivated fetal calf serum and antibiotics (penicillin and streptomycin, Gibco-BRL). Cell growth and viability were assessed by cell count (hemocytometer) and trypan blue dye exclusion protocols.
Preparation of peripheral blood mononuclear cells (PBMC)
PBMC were extracted from diluted venous blood from the patient with acute ATL (see above) and from one healthy seronegative individual by Hypaque-Ficoll centrifugation (Lymphoprep; Nyegaard, Norway). Cells were cultured in RPMI 1640 medium supplemented with 10% heat-inactivated fetal calf serum, antibiotics, 100 U/ml recombinant human IL-2 (Boehringer, Mannheim, Germany) and 1 ng/ml phytohemagglutinin. Cells were maintained at 37°C in a 5% CO 2 humidified atmosphere.
Cell growth and cytotoxicity
Test drugs and vehicles only were added to HuT-102, MT-2, CEM, Jurkat cells, fresh ATL cells and PBMC from healthy donor at the initiation of culture, and the number of viable cells was counted on a daily basis using a hemocytometer and the trypan blue dye exclusion assay. For fresh ATL cells, IL-2 was maintained during treatment with AZT and/or IFN. Growth inhibition was expressed as percentage of corresponding control. Each experiment was performed in triplicate and repeated at least twice.
DNA content analysis
Cells were harvested at different times after treatment, washed twice with cold PBS and fixed in ethanol (−20°C) overnight at 4°C. Subsequently, cells were rinsed with PBS, treated with Tris-HCl buffer (pH 7.4) containing 1% RNase and stained with propidium iodide (PI) 100 g/ml (final concentration). Distribution of cells with different DNA contents was determined using a FACScan flow cytometer (Becton Dickinson, San Jose, CA, USA). In each sample, 10 000 ungated events were acquired. Analysis of cell cycle distribution (including apoptosis) was performed using Modfit software (Becton Dickinson).
Apoptosis determination
The terminal deoxytransferase (TdT)-mediated dUTP nick end labeling (TUNEL) assay was used to monitor the extent of DNA fragmentation as a measure of apoptosis. The assay was performed according to the recommendations of the manufacLeukemia turer (Boehringer). Fluorescein-conjugated dUTP incorporated in nucleotide polymers was detected and quantified using flow cytometry. Approximately 10 000 cells per sample were acquired and analyzed using Cell-Quest software (Becton Dickinson).
Expression of T cell markers
This was assessed by standard indirect immuno-fluorescence (IF) and cytofluorographic analysis using a panel of monoclonal antibodies that recognize distinct T-associated or Trestricted surface antigens, including CD2, CD3, CD4, CD7 and CD8, as well as the B cell restricted antigens CD19 and CD20. Other monoclonal antibodies recognizing the lowaffinity II-2R ␣ chain (IL-2R␣), HLA-DR and CD33 (myeloid marker) were also used.
Briefly, control or test cultures were washed in PBS, and resuspended at the indicated concentration (typically 10 6 cells/ml) in RPMI-1640. The cells were then incubated with the primary antibody for 30 min on ice and washed once with PBS. FITC-or PE-labeled secondary antibody was then added, and the cells were incubated for an additional 30 min on ice, following which they were washed and analyzed by flow cytometry. The percentage of cells positive for a specific surface marker was calculated after analysis of 3000-5000 cells.
Western blot analysis
Approximately 10 7 cells from various treatments were solubilized at 4°C in lysis buffer (0.01 M Tris-Cl (pH 7.4), 0.5% sodium deoxycholate, 0.5% triton X-100, 0.05% SDS). The samples (50 g) were loaded on to a 12% SDS-polyacrylamide gel, subjected to electrophoresis, and transferred to nitrocellulose membrane that was subsequently stained with 0.2% Ponceau red to assure equal protein loading and transfer. After blocking of the membrane in 1% bovine serum albumin (BSA), the blots were reacted with 1:5000 dilution of the rabbit polyclonal anti-bcl-2 (Santa Cruz, CA, USA) or 1:1000 dilution of the mouse monoclonal anti p53 (Upstate Biotechnology, NY, USA) specific antibodies. After washing, the blots were incubated with secondary antibody conjugated to HRP and the signal was detected using the ECL detection kit (Amersham, Buckingham, UK).
Southern blot analysis
Total DNA was extracted from 10 7 PBMC from the acute ATL patient at diagnosis and subsequently monthly during AZT/IFN therapy. 10 g of total genomic DNA was digested by EcoRI (Boehringer) and subjected to electrophoresis on 0.7% agarose gel. Equal DNA loading was assessed by spectrophotometry before gel loading and by ethidium bromide staining of the agarose gel. Southern blot analysis was performed as previously described 10 using HTLV-I full genomic probe pMT-2.
Results
We have utilized freshly isolated cells from a patient with acute ATL and an established model for ATL in vitro, HuT-102 and MT-2 cell lines, to investigate the effect of AZT and IFN treatment on ATL cells. We studied different cellular parameters that included cell growth, cell cycle analysis, apoptosis and expression of apoptosis regulators (bcl-2 and p53).
Proliferation of HTLV-I positive cell lines is not inhibited by the combination of AZT and IFN
Cell lines were incubated with different concentrations of AZT and IFN for 24, 48, 72 h, 10 days and 17 days as described in Materials and methods. In HTLV-I infected cell lines (HuT-102: Figure 1 ; MT-2: data not shown), cell growth was not significantly affected by AZT and IFN treatment. The threshold of 50% inhibition was never reached with AZT alone or IFN alone at any time point. With the combination of AZT and IFN, this threshold of more than 50% inhibition was only reached at 72 h of culture when suprapharmacological doses of AZT (50 M) and IFN (1000 U/ml) were used. Moreover, the effect of the combination was additive rather than synergistic in contrast to the clinical results. Also, these effects were less pronounced in ATL-derived cell lines in comparison to the control cell lines (CEM: Figure 1 ; MT-2: data not shown). 
The combination of AZT and IFN did not induce cell cycle arrest in vitro
In order to investigate whether the inhibition of cell proliferation was due to cell cycle arrest or apoptosis, cell cycle analysis was performed by measuring DNA content as described in Materials and methods. No major modification of the distribution of the different cell cycle phases (G 0 /G 1 , S and G 2 /M phases) was observed except a moderate increase in the percentage of cells in S phase in AZT-treated cells resulting in a decrease in the percentage of cells in the G 0 /G 1 phases (Figure 2) . A dose effect was observed and this phenomenon is related to the peculiar toxicity of AZT (DNA incorporation and cell cycle arrest in S phase). In HuT-102 and MT-2 cell lines, no significant increase in the incorporation of AZT was noted when IFN was added, as reflected by similar percentage of cells in the G 0 /G 1 phases. No difference was observed between HTLV-I positive and negative cells (data not shown).
The combination of AZT and IFN did not induce apoptosis in vitro
Since the effect of the combination of AZT and IFN could involve cell death mechanisms, we employed cell cycle Leukemia analysis and the TUNEL assay for the evaluation of apoptosis. The pre-G 0 /G 1 phase, which is the typical DNA profile of apoptotic cells was not present in HuT-102 cells treated with the combination of AZT and IFN and no synergistic effect on apoptosis was observed between AZT and IFN (data not shown). Using the TUNEL assay, no significant increase in the percentage of apoptotic cells, was observed in HuT-102 cells treated with the combination of 50 M AZT and 1000 U/ml of IFN (Figure 3) . CEM cells exhibited the same behavior. Thus, the induction of apoptosis by this combination was ruled out.
The combination of AZT and IFN did not modify the expression of apoptosis regulatory proteins p53 and bcl-2
The anti-apoptotic protein bcl-2 and the tumor suppresser gene product p53 were constitutively expressed in HuT-102 cells and could be detected by Western blot. However, their level of expression was not significantly altered by AZT and IFN treatment (Figure 4 ). The extent of minor changes in expression could not explain the dramatic effect observed in vivo.
The combination of AZT and IFN did not modify the expression of T cell activation markers
The activation state of ATL-derived cells (HuT-102) as reflected by the constitutive expression of the T cell activation markers (CD25, HLA-DR) was unaltered by the AZT and IFN
Figure 4
Effects of IFN, AZT and their combination on the expression of bcl-2 and p53 by Western blot in the leukemic cell line treatment, even at suprapharmacological doses (data not shown).
The combination of AZT and IFN decreased the viral load in vivo by a non-cytotoxic effect
In order to rule out resistance acquired during the long-term culture of ATL cell lines, we investigated the effect of this combination on the viral load in vivo and on the growth of freshly isolated ATL cells from the patient.
The viral load was evaluated in an acute ATL patient at different time points by Southern blot as described in Materials and methods. As shown in Figure 5 , a progressive decrease in the total proviral DNA was observed concomitantly with the patient response to AZT and IFN therapy. Interestingly, after 6 months of treatment when the patient achieved CR, no clonal proviral genomic DNA was detectable by Southern blot analysis suggesting a very low persistent viral load in vivo. Four years later, the patient is still in complete remission on AZT/IFN maintenance therapy with persistently negative detection of clonal proviral DNA by Southern blot analysis.
Freshly isolated ATL cells were isolated from this patient at diagnosis and treated by AZT and IFN in vitro as described in Materials and methods. At 72 h of culture, no effect on cell growth was observed with AZT, IFN and their combination ( Figure 5 ). Similar results were obtained using PBMC from healthy HTLV-I seronegative donor (data not shown). The patient fresh ATL cells were maintained in culture for 3 weeks in the presence of II-2. Interestingly, at this time of culture, AZT and AZT/IFN combination exerted a significant inhibition of cell growth despite the continuous presence of IL-2 ( Figure 5 ).
Discussion
ATL is an aggressive malignancy of mature activated T cells, with poor prognosis. Although clinical trials reported by us and others demonstrated the efficacy of the combination of AZT and IFN in the treatment of ATL, 4-6 the mechanism of action of this combination remains to be elucidated.
AZT is a thymidine analogue currently used in treating acquired immunodeficiency syndrome and HIV seropositive individuals. Once phosphorylated to AZT-TP by mammalian thymidine kinase, AZT exerts its antiviral activity through incorporation into proviral DNA and consequently, by blocking further chain elongation. AZT does not possess a significant anti-neoplastic activity per se, since it is a poor substrate for mammalian DNA polymerase-␣. However, AZT cytotoxicity against several tumor targets may be augmented by combining AZT with inhibitors of de novo thymidylate synthesis, including 5-fluorouracil, methotrexate, hydroxyurea, as well as IFN. Thus, the synergy between AZT and IFN in the treatment of ATL patients may therefore involve a direct cytotoxic effect, as described for the chronic myeloid leukemia cell line K562. In this cell line the incorporation into cell's DNA and the anti-neoplastic activity of AZT was increased by IFN as a consequence of the inhibition of de novo thymidylate synthesis resulting in chain elongation block. 11 The data we present in this manuscript represent compelling evidence that the therapeutic effect of the combination of AZT and IFN in ATL is not through direct cytotoxic effect of these drugs on the leukemic cells. Indeed, pharmacological and suprapharmacological doses of AZT, IFN and their combination failed to induce any significant inhibition of cell proliferation, cell cycle arrest or apoptosis on two HTLV-I positive cell lines even in long-term culture (14 days). A direct anti-viral effect is also to be considered. Zidovudine was shown to suppress the transformation of normal peripheral blood lymphocytes cocultured with HTLV-I transformed cell lines. Moreover, zidovudine inhibited HTLV-I replication and expression in a rabbit model of ATL at doses lower than those required for direct cytotoxicity. 12 Similarly, the clinical benefit of interferon alone in some patients has been suggested as a direct anti-viral effect against HTLV-I. 13 Although the level of expression of the HTLV-I structural proteins in HuT-102 and MT-2 cell lines was not modified by AZT and IFN treatment (data not shown), the in vivo modulation of the viral expression, replication and/or an indirect effect through modulation of the anti-viral immunity by these two anti-viral drugs represents an interesting and likely alternative hypothesis. The direct demonstration of this latter hypothesis is prohibited by the well-known difficulty in detecting HTLV-I replication and/or expression in ATL patients in vivo. The progressive decrease in the viral load that we observed in an ATL patient who achieved CR under AZT and IFN therapy while his leukemic cells were resistant to this treatment in vitro may represent an indirect demonstration.
